Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)
About the study
The objective of this study is to assess the efficacy, safety, and pharmacokinetics of NBI-921352 as adjunctive therapy for seizures in subjects with SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE).
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
SCN8A Developmental and Epileptic Encephalopathy Syndrome
Age (in years)
2 - 21
Phase
Phase 2
Participants needed
52
Est. Completion Date
Feb 29, 2024
Treatment type
Interventional
Sponsor
Neurocrine Biosciences
ClinicalTrials.gov identifier
NCT04873869
Study number
NBI-921352-DEE2012
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?